A provocative question for the #ESMO26 lower-GI panel:
Post-BREAKWATER, if BRAF V600E mCRC progresses on FOLFOX + encorafenib/cetuximab, could we switch to FOLFIRI + EC—or vice versa?
Can changing the chemo backbone preserve targeted benefit beyond progression?
37 浏览 · 1 赞 · 0 转发 · 0 回复
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Targeted Oncology · x.com